FDA Clears Zepbound as New Option for Obesity Treatment

FDA Approves Zepbound (Tirzepatide) for Chronic Weight Management

The FDA approved Zepbound on November 8, 2023. Officials cleared the once-weekly injectable drug for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes or obstructive sleep apnea. The agency based its decision on phase 3 results from the SURMOUNT-1 trial, which recorded mean weight reductions of 15.0 percent at the 5-milligram dose, 19.5 percent at 10 milligrams and 20.9 percent at 15 milligrams after 72 weeks, compared with 3.1 percent for placebo. [1][2]

What this means

The decision grants a distinct brand and indication for tirzepatide in weight management separate from its earlier approval as Mounjaro for type 2 diabetes. Trial data associate the dual GIP and GLP-1 receptor agonist with dose-dependent weight change when added to lifestyle measures. Insurance coverage, tolerability and the absence of certain long-term datasets are expected to shape how the medication fits into existing care patterns.

Key takeaways

• The FDA approved Zepbound for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity, as an adjunct to diet and exercise. [1]
• SURMOUNT-1 trial results showed mean weight loss of 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg versus 3.1 percent for placebo at 72 weeks. [2]
• Common adverse reactions occurring in 5 percent or more of participants included nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue and hypersensitivity reactions. [1]
• The drug carries a boxed warning for risk of thyroid C-cell tumors based on rodent studies and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. [1]
• Regulators based the approval on the SURMOUNT clinical development program. [3]

The SURMOUNT-1 study enrolled adults with obesity or overweight. Its primary endpoint measured mean percent change in body weight from baseline to week 72. [3]

Results published in the New England Journal of Medicine confirmed statistically significant, dose-dependent weight loss versus placebo. [2]

Gastrointestinal events ranked as the most common side effects in the trial. These effects were dose-dependent and often eased with time. [1]

Discontinuation rates ran higher in the Zepbound groups. Roughly 5 to 7 percent of participants on the drug stopped treatment compared with 2 to 3 percent on placebo.

Both Zepbound and Mounjaro contain the same active ingredient. The FDA granted Zepbound its approval for chronic weight management while Mounjaro holds approval for type 2 diabetes. [1]

Limitations

The evidence shows clear weight reduction at 72 weeks in the studied population but does not include completed long-term cardiovascular outcomes data specific to obesity, which ongoing trials continue to collect. High discontinuation rates tied to gastrointestinal tolerability appeared in the trials. Researchers have not studied or approved the drug for pediatric populations or for adults who fall outside the BMI and comorbidity criteria. Cost and insurance coverage may limit real-world access despite the regulatory approval.

FAQ

What were the primary efficacy endpoints and results from the pivotal SURMOUNT-1 trial supporting approval?
The trial measured percent change in body weight at 72 weeks. Mean reductions reached 15.0 percent, 19.5 percent, and 20.9 percent across the three doses versus 3.1 percent for placebo. [2][3]

What are the dosing schedule, contraindications, and most common adverse reactions for Zepbound?
It is given once weekly by subcutaneous injection. The drug is contraindicated in patients with a history of medullary thyroid carcinoma or MEN 2. Nausea, diarrhea, and vomiting ranked among the most frequent reactions. [1]

How does the indication and mechanism of Zepbound differ from Mounjaro (tirzepatide)?
Zepbound holds approval for chronic weight management while Mounjaro is approved for type 2 diabetes. Both act as dual GIP and GLP-1 receptor agonists. [1]